136 related articles for article (PubMed ID: 32158439)
1. Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug.
Mori G; Orena BS; Chiarelli LR; Degiacomi G; Riabova O; Sammartino JC; Makarov V; Riccardi G; Pasca MR
Front Microbiol; 2020; 11():292. PubMed ID: 32158439
[TBL] [Abstract][Full Text] [Related]
2. New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053.
Chiarelli LR; Salina EG; Mori G; Azhikina T; Riabova O; Lepioshkin A; Grigorov A; Forbak M; Madacki J; Orena BS; Manfredi M; Gosetti F; Buzzi A; Degiacomi G; Sammartino JC; Marengo E; Korduláková J; Riccardi G; Mikušová K; Makarov V; Pasca MR
ACS Infect Dis; 2020 Feb; 6(2):313-323. PubMed ID: 31729215
[TBL] [Abstract][Full Text] [Related]
3. Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis.
Albesa-Jové D; Chiarelli LR; Makarov V; Pasca MR; Urresti S; Mori G; Salina E; Vocat A; Comino N; Mohorko E; Ryabova S; Pfieiffer B; Lopes Ribeiro AL; Rodrigo-Unzueta A; Tersa M; Zanoni G; Buroni S; Altmann KH; Hartkoorn RC; Glockshuber R; Cole ST; Riccardi G; Guerin ME
ACS Chem Biol; 2014 Jul; 9(7):1567-75. PubMed ID: 24877756
[TBL] [Abstract][Full Text] [Related]
4. The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053.
Albesa-Jové D; Comino N; Tersa M; Mohorko E; Urresti S; Dainese E; Chiarelli LR; Pasca MR; Manganelli R; Makarov V; Riccardi G; Svergun DI; Glockshuber R; Guerin ME
J Biol Chem; 2015 Dec; 290(52):31077-89. PubMed ID: 26546681
[TBL] [Abstract][Full Text] [Related]
5. The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of
Rosado LA; Wahni K; Degiacomi G; Pedre B; Young D; de la Rubia AG; Boldrin F; Martens E; Marcos-Pascual L; Sancho-Vaello E; Albesa-Jové D; Provvedi R; Martin C; Makarov V; Versées W; Verniest G; Guerin ME; Mateos LM; Manganelli R; Messens J
J Biol Chem; 2017 Aug; 292(32):13097-13110. PubMed ID: 28620052
[TBL] [Abstract][Full Text] [Related]
6. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. SigH stress response mediates killing of Mycobacterium tuberculosis by activating nitronaphthofuran prodrugs via induction of Mrx2 expression.
Cioetto-Mazzabò L; Boldrin F; Beauvineau C; Speth M; Marina A; Namouchi A; Segafreddo G; Cimino M; Favre-Rochex S; Balasingham S; Trastoy B; Munier-Lehmann H; Griffiths G; Gicquel B; Guerin ME; Manganelli R; Alonso-Rodríguez N
Nucleic Acids Res; 2023 Jan; 51(1):144-165. PubMed ID: 36546765
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
12. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
14. New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis.
Salina EG; Ryabova O; Vocat A; Nikonenko B; Cole ST; Makarov V
J Infect Chemother; 2017 Nov; 23(11):794-797. PubMed ID: 28527650
[TBL] [Abstract][Full Text] [Related]
15. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a cofactor-independent inhibitor of
Xia Y; Zhou Y; Carter DS; McNeil MB; Choi W; Halladay J; Berry PW; Mao W; Hernandez V; O'Malley T; Korkegian A; Sunde B; Flint L; Woolhiser LK; Scherman MS; Gruppo V; Hastings C; Robertson GT; Ioerger TR; Sacchettini J; Tonge PJ; Lenaerts AJ; Parish T; Alley M
Life Sci Alliance; 2018 Jun; 1(3):e201800025. PubMed ID: 30456352
[TBL] [Abstract][Full Text] [Related]
17.
Leechawengwongs M; Prammananan T; Jaitrong S; Billamas P; Makhao N; Thamnongdee N; Thanormchat A; Phurattanakornkul A; Rattanarangsee S; Ratanajaraya C; Disratthakit A; Chaiprasert A
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061759
[TBL] [Abstract][Full Text] [Related]
18. Capreomycin is active against non-replicating M. tuberculosis.
Heifets L; Simon J; Pham V
Ann Clin Microbiol Antimicrob; 2005 Apr; 4():6. PubMed ID: 15804353
[TBL] [Abstract][Full Text] [Related]
19. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.
Grant SS; Wellington S; Kawate T; Desjardins CA; Silvis MR; Wivagg C; Thompson M; Gordon K; Kazyanskaya E; Nietupski R; Haseley N; Iwase N; Earl AM; Fitzgerald M; Hung DT
Cell Chem Biol; 2016 Jun; 23(6):666-77. PubMed ID: 27321573
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
